更高的神经元促进和强化与APOE4被抑制的 ангиотензинII
Sarah B Scheinman1, Kuei Y Tseng1, Simon Alford1
1Department of Anatomy and Cell Biology, University of Illinois at Chicago, 808 S. Wood St. Rm 578 MC 512, Chicago, IL, 60612, USA.
Molecular neurobiology
|August 17, 2023
概括
阿尔茨海默病 (AD) 模型中的APOE4基因变异和粉样β与海马活动减少,但突触可塑性增强有关. ангиотензин II 进一步损害了这种可塑性,这表明在早期 AD 进展中存在复杂的相互作用.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 涉及逐渐的海马体退化.
- 早期识别调节神经元功能的因素对于预防AD至关重要.
- APOE基因型和血管新生素II是影响神经元功能的关键AD风险因素.
研究的目的:
- 研究APOE基因型 (APOE3与APOE4) 和血管素II对AD相关小鼠模型中海马神经元功能的影响.
- 评估E3FAD和E4FAD小鼠的突触传播,突触前和突触后活动.
主要方法:
- 电生理学技术被用于测量基底突触传输,配对脉冲促进 (PPF) 和长期强化 (LTP).
- 对表达人类APOE3 (E3FAD) 或APOE4 (E4FAD) 的小鼠进行了实验,这些小鼠过度产生粉样β (Aβ).
- 评估了外源性 ангиотензин II 对海马体LTP 的影响.
主要成果:
- 与E3FAD小鼠相比,E4FAD小鼠表现出较低的基础突触活性.
- 与E3FAD小鼠相比,E4FAD小鼠在海马中显示出更高的PPF和LTP水平.
- 在E3FAD和E4FAD小鼠中, ангиотензинII显著抑制了海马的LTP.
结论:
- APOE4和Aβ与海马体表型的基底活动减少和高频刺激反应增强有关.
- ангиотензинII抑制了这种增强的反应,这表明在AD病变发生过程中,海马活动,APOE4和 ангиотензинII之间存在潜在的联系机制.
- 这些发现提供了关于早期AD机制和潜在治疗点的见解.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
690
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
690
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:25Antihypertensive Drugs: Direct Renin Inhibitors
680
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
680
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
780
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
780
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:25Adrenergic Agonists: Indirect-Acting Agents
1.7K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.7K